查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1835212

H1N1 疫苗市场按产品类型、技术、最终用户、分销管道、剂型和年龄组划分 - 2025-2032 年全球预测

H1N1 Vaccines Market by Product Type, Technology, End User, Distribution Channel, Dosage Form, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，H1N1 疫苗市场规模将成长至 1,623.2 亿美元，复合年增长率为 36.51%。

主要市场统计数据
基准年2024年 134.5亿美元
预计2025年 184.2亿美元
预测年份：2032年 1623.2亿美元
复合年增长率（%） 36.51%

透过临床、製造、监管和分销视角建构当代大流行性流感疫苗环境，以供策略决策

本执行摘要提炼了塑造当今 H1N1 疫苗格局的关键策略、营运和监管方面。疫苗接种计划、生产平台和采购政策与不断变化的公共卫生优先事项和技术进步交织在一起，构成了一个复杂的环境，製造商、卫生系统和分销合作伙伴必须紧密合作。本摘要介绍了决策者在将研发投资、供应链弹性和商业策略与全球疫苗接种宣传活动的现实情况相结合时应考虑的关键主题。

这些因素包括免疫抗原性、安全性、给药方式和年龄特异性疗效。同时，製造方法的选择——细胞、卵细胞或重组——会影响前置作业时间、产量以及对抗原漂移的适应性。这些技术变数直接影响采购週期、监管提交策略和共同生产设计。

公共卫生需求持续要求可靠的疫苗供应和公平分配。製造商、医院系统、诊所和公共卫生中心之间的有效协调对于将疫苗供应转化为全民保护至关重要。在此背景下，分销管道和剂型之间的相互作用正在塑造现场物流、低温运输要求和管理工作流程。以下章节将探讨转型变革、关税的影响、市场区隔和区域考量、竞争定位以及实用建议，以帮助相关人员做出短期营运选择和长期策略投资。

确定关键的结构性变化，透过创新和营运弹性重塑 H1N1 疫苗的开发、生产和分销

在平台创新、供应链现代化和相关人员预期转变的推动下，H1N1疫苗格局正在发生重大变化。重组抗原生产和细胞製造的挑战正在改变疫苗株更新时间表，并实现更灵活的生产力计画，从而挑战传统的基于鸡蛋的模式。同时，低温运输监控、订单管理和库存预测的数位化正在提高分销的可预测性，并提升对整个价值链透明度的期望。

市场参与企业正在回应日益增长的差异化剂型需求，例如简化给药的预填充式注射器和优化大规模疫苗宣传活动储存效率的多剂量管瓶。这种便利性和成本效益之间的推拉动态促使製造商拓宽其产品组合策略，并考虑契约製造和填充完成伙伴关係，以加速市场准备。监管机构越来越多地接受能够证明平台可比性的资料包，而不是依赖历史路径，从而促进采用新的製造方法，同时保持安全性和有效性标准。

同时，公共卫生和采购组织正在优先考虑韧性。双重采购、策略储备和地理分散的製造地正在从可选的最佳实践转变为业务必要。这种转变正在推动商业谈判和伙伴关係模式的新变化。买家寻求更大的供应连续性保证，而供应商则优先考虑营运灵活性，以应对不断变化的需求状况。由此形成了一个更具协作性的生态系统，其中对数据主导规划、伙伴关係和适应性製造平台的投资将决定竞争地位。

分析美国关税政策将如何改变大流行性流感疫苗相关人员的采购经济、供应链设计和采购复杂性

2025年美国关税趋势将对大流行性流感疫苗生态系统产生重大影响，影响投入成本、供应商选择和跨国生产策略。关税会增加进口零件（从专用试剂和一次性生物加工耗材到包装材料和某些成品）的到岸成本，这将直接影响製造业的经济效益。这些成本压力可能会促使製造商重新评估筹资策略，倾向于选择国内供应商和具有相容监管和品质框架的近岸外包选项。因此，随着供应链被检验，此类转变可能会改变前置作业时间并带来转型复杂性。

卫生系统和公共机构的采购和承包团队会受到关税带来的下游成本影响。即使关税政策涵盖某些医疗用品和关键投入品的豁免，与关税分类、海关文件和合规审核相关的行政负担也会加剧贸易摩擦。此类摩擦会延迟订单履行，使即时库存策略复杂化，并促使买家优先选择拥有整合全球供应链能力、能够主动管理海关风险的供应商。

製造商将透过重新规划其采购布局并协商包含关税意外事件的长期供应合约来应对。拥有多种平台能力（例如细胞疫苗、蛋疫苗和重组疫苗）的公司可以调整其生产分配，以降低特定区域的成本风险。同时，投资关税专业知识和灵活物流解决方案的契约製造製造商和经销商将成为首选合作伙伴，因为它们可以降低关税波动带来的营运风险。因此，政策制定者和产业领导者应将关税政策视为营运变数。这意味着他们需要製定整合海关风险评估、基于情境的采购条款以及对供应链透明度工具的投资的计划，以预测疫苗供应情况并维持具有成本效益的生产路径。

发现推动细分的细微差别，包括产品类型、技术、最终用户、通路、剂型和年龄组，以製定您的策略

细分市场层面的动态揭示了差异化的商业性和营运重点，这些重点应体现在产品组合和通路策略中。按产品类型，我们考察了灭活疫苗和减毒活病毒疫苗。灭活疫苗进一步检视了细胞疫苗、鸡胚疫苗和重组疫苗。活病毒疫苗进一步考察了鸡胚疫苗。这些产品差异会影响生产时间表、监管申报和临床医生偏好，其中细胞疫苗和重组灭活疫苗具有适应症优势，而鸡胚减毒活活病毒疫苗则适用于特定的项目应用。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用基于mRNA的递送平台加速H1N1疫苗生产时间表
  • 针对病毒株保守的H1N1抗原决定位点的通用流感疫苗研究进展
  • 引进耐热 H1N1 疫苗配方，提高低温运输独立性
  • 扩大生技公司与政府机构之间的战略伙伴关係，为应对 H1N1 流感大流行做好准备
  • 开发无针鼻内 H1N1 疫苗以提高患者依从性和覆盖率
  • 人工智慧驱动的监测数据整合可预测 H1N1 疫情热点并指导疫苗分发
  • 增加对细胞培养 H1N1 疫苗生产能力的投资，以满足激增的需求
  • 简化疫情期间 H1N1 疫苗紧急使用授权规定

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. H1N1疫苗市场（依产品类型）

  • 灭活疫苗
    • 基于细胞
    • 鸡蛋为主
    • 重组
  • 减毒活疫苗
    • 鸡蛋为主

9. H1N1疫苗市场（依技术）

  • 基于细胞
  • 鸡蛋为主
  • 重组

10. H1N1 疫苗市场（依最终用户）

  • 诊所
  • 医院
  • 公共卫生中心

11. H1N1疫苗市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

12. H1N1疫苗市场（按剂型）

  • 多剂量管瓶
  • 预填充式注射器

13. H1N1疫苗市场（依年龄层）

  • 成人
  • 孩子
  • 进阶的

14. H1N1疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. H1N1疫苗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. H1N1疫苗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Sanofi Pasteur SA
    • GlaxoSmithKline plc
    • CSL Seqirus Pty Ltd
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Moderna, Inc.
    • Bharat Biotech International Limited
    • Bavarian Nordic A/S
    • Panacea Biotec Limited
Product Code: MRR-437E9896A50B

The H1N1 Vaccines Market is projected to grow by USD 162.32 billion at a CAGR of 36.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.45 billion
Estimated Year [2025] USD 18.42 billion
Forecast Year [2032] USD 162.32 billion
CAGR (%) 36.51%

Framing the contemporary H1N1 vaccine environment through clinical, manufacturing, regulatory, and distribution lenses for strategic decision-making

The present executive summary distills the critical strategic, operational, and regulatory dimensions shaping the H1N1 vaccine landscape today. Vaccination programs, manufacturing platforms, and procurement policies intersect with evolving public health priorities and technological advances, creating a complex environment in which manufacturers, health systems, and distribution partners must coordinate closely. This summary frames core themes that decision-makers should weigh when aligning R&D investments, supply chain resilience, and commercial strategies with the realities of global immunization campaigns.

Clinical considerations remain central: immunogenicity, safety profiles, dosing formats, and age-specific efficacy influence product selection at the policy level and acceptance among clinicians and the public. Concurrently, manufacturing choices-whether cell-based, egg-based, or recombinant-affect lead times, throughput, and adaptability to antigenic drift. These technical variables have direct implications for procurement cycles, regulatory filing strategies, and the design of collaborative manufacturing arrangements.

Public health imperatives continue to drive demand for dependable vaccine supply and equitable distribution. Effective coordination between manufacturers, hospital systems, clinics, and public health centers is necessary to translate vaccine availability into population-level protection. In this context, the interplay between distribution channels and dosage formats shapes on-the-ground logistics, cold-chain requirements, and administration workflows. The following sections unpack transformative shifts, tariff impacts, segmentation and regional insights, competitive positioning, and actionable recommendations to help stakeholders navigate near-term operational choices and longer-term strategic investments.

Identifying the profound structural changes reshaping H1N1 vaccine development, production, and distribution driven by innovation and operational resilience

The H1N1 vaccine landscape is undergoing transformative shifts driven by platform innovation, supply-chain modernization, and changing stakeholder expectations. Advances in recombinant antigen production and cell-based manufacturing are altering timelines for strain updates and enabling more flexible capacity planning, thereby challenging legacy egg-based paradigms. Concurrently, digitalization in cold-chain monitoring, order management, and inventory forecasting is improving the predictability of distribution while raising expectations for transparency across the value chain.

Market participants are responding to heightened demand for differentiated dosage forms, including pre-filled syringes that simplify administration and multi-dose vials that optimize storage efficiency for mass immunization campaigns. This push-pull dynamic between convenience and cost-efficiency is prompting manufacturers to broaden portfolio strategies and to consider contract manufacturing or fill-finish partnerships to accelerate market readiness. Regulators are increasingly receptive to data packages that demonstrate platform comparability rather than relying on historical pathways, which is expediting the introduction of novel manufacturing approaches while maintaining safety and efficacy standards.

At the same time, public health agencies and procurement bodies are emphasizing resilience: dual sourcing, strategic stockpiles, and geographic diversification of manufacturing footprints have moved from optional best practices to operational imperatives. These shifts are reframing commercial negotiations and partnership models, as buyers seek greater assurances of supply continuity and suppliers focus on operational flexibility to meet variable demand profiles. The result is a more collaborative ecosystem in which data-driven planning, cross-sector partnerships, and investment in adaptable manufacturing platforms determine competitive positioning.

Analyzing how tariff policy in the United States will alter sourcing economics, supply chain design, and procurement complexity for H1N1 vaccine stakeholders

U.S. tariff dynamics in 2025 carry material implications for the H1N1 vaccine ecosystem by influencing input costs, supplier selection, and cross-border manufacturing strategies. Tariff measures that raise the landed cost of imported components-ranging from specialized reagents and single-use bioprocessing consumables to packaging materials and certain finished goods-directly affect manufacturing economics. These cost pressures incentivize manufacturers to reassess sourcing strategies, potentially favoring domestic suppliers or nearshoring options where regulatory and quality frameworks are compatible. In turn, such shifts can alter lead times and introduce transitional complexity as supply chains are revalidated.

Procurement and contracting teams within health systems and public agencies experience the downstream effects of tariff-induced cost variability. Even when tariff policy includes exemptions for certain medical goods or critical inputs, administrative burdens associated with tariff classification, customs documentation, and compliance audits increase transactional friction. This friction can slow order fulfillment, complicate just-in-time inventory strategies, and encourage buyers to prioritize suppliers with integrated global supply chain capabilities that manage customs risk proactively.

Manufacturers respond by redesigning sourcing footprints and negotiating longer-term supply agreements that incorporate tariff contingencies. Firms with diverse platform capabilities-cell-based, egg-based, and recombinant-can adapt manufacturing allocations to mitigate localized cost exposures. Meanwhile, contract manufacturers and distributors that invest in customs expertise and flexible logistics solutions become preferred partners because they reduce the operational risk arising from tariff volatility. Policymakers and industry leaders should therefore treat tariff policy as an operational variable: planning must integrate customs risk assessment, scenario-based procurement terms, and investment in supply chain transparency tools to preserve predictable vaccine availability and maintain cost-effective manufacturing pathways.

Uncovering nuanced segmentation-driven imperatives across product types, technologies, end users, channels, dosage forms, and age cohorts that shape strategy

Segment-level dynamics reveal differentiated commercial and operational priorities that should inform portfolio and channel strategies. Based on Product Type, the market is studied across Inactivated Vaccine and Live Attenuated Vaccine. The Inactivated Vaccine is further studied across Cell Based, Egg Based, and Recombinant. The Live Attenuated Vaccine is further studied across Egg Based. These product distinctions influence manufacturing timelines, regulatory dossiers, and clinician preferences, with cell-based and recombinant inactivated vaccines offering adaptation advantages and egg-based live attenuated formats retaining utility for specific programmatic uses.

Based on Technology, the market is studied across Cell Based, Egg Based, and Recombinant. Technology choice drives capital expenditure profiles, facility design, and skilled workforce requirements, and it shapes the agility with which manufacturers can respond to strain changes. Based on End User, the market is studied across Clinics, Hospitals, and Public Health Centers. End-user segmentation highlights differences in purchase cadence, cold-chain handling capabilities, and clinical administration workflows, which in turn inform packaging and dosage format decisions.

Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Channel economics and regulatory constraints vary significantly, prompting manufacturers and distributors to tailor distribution agreements and commercial support models to each channel's operational realities. Based on Dosage Form, the market is studied across Multi-Dose Vials and Pre-Filled Syringes. Dosage form choices impact wastage rates, on-site administration speed, and inventory management policies. Based on Age Group, the market is studied across Adults, Children, and Seniors. Age-segmented clinical considerations affect labeling, recommended dosing schedules, and communication strategies directed at caregivers and clinicians. Synthesizing these segmentation layers reveals where investment in platform flexibility, tailored packaging, and targeted stakeholder engagement can deliver the greatest near-term and mid-term returns.

Evaluating how regional regulatory, manufacturing, and procurement differences across the Americas, EMEA, and Asia-Pacific dictate operational strategies and partnerships

Regional dynamics create distinct operational conditions and policy environments that influence manufacturing allocation, distribution design, and regulatory engagement. The Americas encompass a diverse mix of advanced manufacturing capacity, centralized procurement programs, and mature public health infrastructures, which support rapid uptake of new vaccine formats but also require robust commercial evidence packages to secure formulary positions. Europe, Middle East & Africa combines highly regulated markets with variable procurement sophistication and evolving local manufacturing ambitions, requiring adaptive regulatory strategies and flexible supply models to serve both high-capacity health systems and resource-constrained settings.

Asia-Pacific presents a heterogeneous landscape characterized by large population centers with rapidly expanding immunization programs, an increasing number of local manufacturing entrants, and a strong emphasis on cost-containment measures. Regional actors prioritize scalability and price efficiency while simultaneously seeking technology transfer partnerships and local fill-finish capacity to reduce dependence on distant supply chains. The geographic mix of regulatory timelines, logistical realities, and procurement architectures means that manufacturers must tailor regulatory submission strategies, commercial contracting terms, and distribution partnerships to local contexts to achieve operational reliability and policy alignment.

Across these regions, differences in cold-chain infrastructure, public procurement cycles, and local manufacturing incentives determine the optimal balance between centrally produced vaccine lots and regionally manufactured fill-finish operations. Strategic regional planning that integrates regulatory intelligence, logistics capability assessments, and stakeholder engagement plans will reduce time-to-deployment risk and enhance alignment with national immunization program priorities.

Profiling company-level strengths and strategic capabilities that determine supply reliability, regulatory agility, and competitive differentiation in H1N1 vaccines

Competitive positioning in the H1N1 vaccine space reflects a combination of platform capability, manufacturing scale, regulatory relationships, and partnership networks. Leading players demonstrate strength by maintaining multi-platform portfolios that include cell-based and recombinant technologies alongside legacy egg-based production, enabling them to allocate production where it is most efficient and to mitigate supply interruptions. Firms that invest in fill-finish capacity and third-party partnerships reduce bottlenecks and better serve diverse distribution channels and dosage form preferences.

Operational excellence-measured by validated quality systems, robust supply assurance processes, and rapid regulatory responsiveness-differentiates companies when procurement bodies evaluate supplier reliability. Strategic alliances with clinical networks, public health agencies, and international procurement entities enhance product uptake and support lifecycle management activities such as post-market surveillance and age-group specific labeling. Companies that integrate data analytics into demand planning and cold-chain monitoring deliver superior fulfillment performance and reduce wastage, strengthening their commercial propositions to hospitals, clinics, and public health centers.

Innovation pipelines that emphasize antigen design, improved adjuvantation where appropriate, and user-friendly dosage forms position companies to capture segments that prioritize ease of administration and improved patient adherence. At the same time, organizations that invest in regulatory intelligence and cross-border compliance expertise shorten market entry timelines in multiple regions, creating a competitive advantage when rapid response to H1N1 strain shifts is required. For stakeholders assessing partnerships or supplier selection, the combination of technology breadth, manufacturing resilience, and demonstrated execution in distribution channels constitutes a meaningful framework for comparison.

Practical and prioritized strategic measures that manufacturers, distributors, and public health partners can deploy to enhance resilience and accelerate adoption

Industry leaders should prioritize a set of actionable moves that align technical capacity with market and public health needs. First, expand platform flexibility by investing in or partnering for cell-based and recombinant capabilities while preserving targeted egg-based capacity where clinically indicated. This approach increases adaptability to antigenic changes and reduces single-technology exposure. Second, formalize supply assurances through multi-sourcing arrangements and contractual clauses that address customs and tariff variability, thereby protecting procurement commitments and minimizing fulfillment disruptions.

Third, optimize dosage form portfolios to match channel and end-user requirements: prioritize pre-filled syringes for settings where administration speed and patient convenience are paramount, and preserve multi-dose vial options for large-scale immunization programs that prioritize storage efficiency. Fourth, strengthen distribution partnerships by embedding digital cold-chain monitoring and collaborative inventory planning tools that reduce wastage and improve transparency for hospitals, clinics, and public health centers. Invest in training and technical support programs to ensure smooth on-the-ground implementation.

Fifth, engage proactively with regulators and procurement bodies to streamline dossier submissions and to secure predictable procurement pathways. Where tariff exposures exist, pursue advocacy for tariff exemptions or harmonized classifications for critical inputs and finished vaccines. Finally, tailor regional strategies to local regulatory and procurement contexts, leveraging partnerships for local fill-finish or technology transfer where appropriate. Taken together, these steps enhance resilience, create commercial differentiation, and support sustained public health impact.

Explaining the multi-source methodology combining stakeholder interviews, regulatory review, and cross-disciplinary validation to ensure practical and reliable insights

The research methodology underpinning this analysis integrates a combination of primary stakeholder engagement, secondary literature synthesis, and cross-functional subject-matter validation to ensure robust, actionable insights. Primary inputs included structured interviews with manufacturing leaders, regulatory experts, procurement officials, and distribution managers to capture operational realities across manufacturing platforms and distribution channels. These interviews focused on production constraints, regulatory pathways, channel-specific administration dynamics, and procurement considerations relevant to clinics, hospitals, and public health centers.

Secondary analysis encompassed an extensive review of technical regulatory guidance, peer-reviewed clinical literature on vaccine platforms, and operational case studies covering fill-finish logistics and cold-chain practices. Cross-validation workshops with experts in manufacturing scale-up and supply chain risk management were used to reconcile divergent views and to test the feasibility of recommended interventions. Where possible, triangulation between qualitative inputs and publicly available regulatory notices or procurement program descriptions was applied to ensure factual consistency.

Findings were synthesized through a segmentation lens that examined product type, technology, end user, distribution channel, dosage form, and age group implications. Regional intelligence was developed by mapping regulatory pathways, manufacturing capacity, and procurement architectures across the Americas, Europe, Middle East & Africa, and Asia-Pacific. This methodological approach emphasizes practical utility for decision-makers by prioritizing operational levers and contextualized strategies rather than speculative scenarios.

Distilling strategic imperatives and operational priorities that collectively enhance readiness, reliability, and public health impact for H1N1 vaccine programs

In summary, the contemporary H1N1 vaccine environment requires integrated strategies that combine platform diversity, supply-chain resilience, and targeted engagement across channels and regions. Technological progress in cell-based and recombinant manufacturing expands operational options and supports faster adaptation to antigenic change, while dosage form and channel preferences dictate the practicalities of deployment at the point of care. Tariff and customs dynamics introduce an additional operational variable that organizations must manage through sourcing flexibility and contractual safeguards.

Competitive advantage accrues to organizations that harmonize technical capability with executional excellence: demonstrated manufacturing quality, established distribution partnerships, and regulatory agility. Region-specific approaches that account for differences in procurement architectures, regulatory timelines, and infrastructure capacity will reduce deployment friction and enhance alignment with national immunization priorities. By executing on the recommended actions-platform investment, supply assurances, dosage form optimization, digital distribution enablement, and proactive regulatory engagement-stakeholders can improve reliability of supply and responsiveness to public health needs.

The insights presented here are intended to inform near-term operational priorities and medium-term strategic planning without presuming a single pathway for all organizations. Decision-makers should use this synthesis to identify the most actionable levers within their influence, align cross-functional teams, and engage relevant external partners to convert strategic intent into operational reality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of mRNA-based delivery platforms to accelerate H1N1 vaccine production timelines
  • 5.2. Advancements in universal influenza vaccine research targeting conserved H1N1 epitopes across strains
  • 5.3. Implementation of thermostable H1N1 vaccine formulations to improve cold chain independence
  • 5.4. Expansion of strategic partnerships between biotech firms and government agencies for H1N1 pandemic preparedness
  • 5.5. Development of needle-free intranasal H1N1 vaccines to enhance patient compliance and coverage
  • 5.6. Integration of AI-driven surveillance data to forecast H1N1 outbreak hotspots and guide vaccine distribution
  • 5.7. Increasing investments in cell-based H1N1 vaccine manufacturing capacity to meet surge demand
  • 5.8. Regulatory streamlining for emergency use authorization of H1N1 vaccines during outbreak surges

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. H1N1 Vaccines Market, by Product Type

  • 8.1. Inactivated Vaccine
    • 8.1.1. Cell Based
    • 8.1.2. Egg Based
    • 8.1.3. Recombinant
  • 8.2. Live Attenuated Vaccine
    • 8.2.1. Egg Based

9. H1N1 Vaccines Market, by Technology

  • 9.1. Cell Based
  • 9.2. Egg Based
  • 9.3. Recombinant

10. H1N1 Vaccines Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Public Health Centers

11. H1N1 Vaccines Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. H1N1 Vaccines Market, by Dosage Form

  • 12.1. Multi-Dose Vials
  • 12.2. Pre-Filled Syringes

13. H1N1 Vaccines Market, by Age Group

  • 13.1. Adults
  • 13.2. Children
  • 13.3. Seniors

14. H1N1 Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. H1N1 Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. H1N1 Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Sanofi Pasteur SA
    • 17.3.2. GlaxoSmithKline plc
    • 17.3.3. CSL Seqirus Pty Ltd
    • 17.3.4. Novartis AG
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Takeda Pharmaceutical Company Limited
    • 17.3.7. Moderna, Inc.
    • 17.3.8. Bharat Biotech International Limited
    • 17.3.9. Bavarian Nordic A/S
    • 17.3.10. Panacea Biotec Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. H1N1 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL H1N1 VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GCC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. GCC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. GCC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 312. GCC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 313. GCC H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 314. GCC H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 315. GCC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. GCC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. GCC H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. GCC H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. GCC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. GCC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. GCC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 322. GCC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 323. GCC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GCC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS H1N1 VACCINES MARKET SIZE, BY END